M&A

Apellis (APLS) Stock Rating Cut by Cantor Fitzgerald Post-Biogen Deal

Published on 4/1/2026

#APLS#M&A#CantorFitzgerald#Biogen
Apellis (APLS) Stock Rating Cut by Cantor Fitzgerald Post-Biogen Deal

AI Summary

Cantor Fitzgerald has downgraded Apellis Pharmaceuticals (APLS) following Biogen's recent acquisition. This decision reflects potential market implications for APLS shares amidst Biogen's active strategic moves. The downgrade is a response to shifts in market sentiment influenced by M&A activities. Investors may want to monitor how this impacts APLS's trading volumes and price movements in the near term.

Source: Read original article (opens in new tab)

Related News

Chinese Officials Meet Citigroup (C) and Goldman Sachs (GS) Leaders
M&A

Chinese Officials Meet Citigroup (C) and Goldman Sachs (GS) Leaders

May 16

TREDEGAR CORP (TG) Form 144 Filing on May 15 Revealed
M&A

TREDEGAR CORP (TG) Form 144 Filing on May 15 Revealed

May 16

NextEra (NEE) and Dominion (D) Discuss $400 Billion Utility Merger
M&A

NextEra (NEE) and Dominion (D) Discuss $400 Billion Utility Merger

May 16

Babcock & Wilcox Enterprises (BW) Files Form 424B5 on May 15
M&A

Babcock & Wilcox Enterprises (BW) Files Form 424B5 on May 15

May 15